Phillip Donenberg

Phillip Donenberg is currently the Director at Taysha Gene Therapies. Prior to their current position, they held various finance-related positions at several companies, most notably Jaguar Gene Therapy, Assertio Therapeutics, Inc., and AveXis, Inc.

Donenberg has been in the finance industry for over 20 years. Phillip began their career at Assertio Therapeutics, Inc. in July 2018 as the Senior Vice President and Chief Financial Officer. In this role, they were responsible for the accounting and financial management processes of the company, including financial statements, certified audits, product sales, accounts receivable and payable, general ledger, payroll and income taxes, budgeting and forecasting, cost analysis, cash management, and treasury management. Phillip also maintained banking and insurance relationships and managed all employee benefits.

In September 2016, Donenberg left Assertio Therapeutics to join AveXis, Inc. as their Senior Vice President and Chief Financial Officer. At AveXis, they oversaw all aspects of the financial management and accounting operations, controls and reporting processes. Phillip was also instrumental in the company's acquisition by Novartis AG in May 2018 for $8.7 billion.

Phillip Donenberg received a B.S. in accountancy from the University of Illinois Urbana-Champaign and is certified as a public accountant in the state of Illinois. Phillip is registered as an inactive certified public accountant in Illinois.